PaTHway Phase 3 Trial Analysis
Cautionary Note on Forward-Looking Statements
This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, such as statements
regarding our future results of operations and financial position, including our business strategy, prospective products, clinical trial results, product approvals and
regulatory pathways, collaborations, licensing or other arrangements, the scope, support progress, results and costs of developing our product candidates or any
other future product candidates, the potential market size and size of the potential patient populations for our product candidates, timing and likelihood of
success, plans and objectives of management for future operations, the scope of protection we are able to establish and maintain for intellectual property rights
covering our product candidates, and future results of current and anticipated products, are forward-looking statements. These forward-looking statements are
based on our current expectations and beliefs, as well as assumptions concerning future events. These statements involve known and unknown risks,
uncertainties and other factors that could cause our actual results to differ materially from the results discussed in the forward-looking statements. These risks,
uncertainties and other factors are more fully described in our reports filed with or submitted to the Securities and Exchange Commission, including, without
limitation, our preliminary prospectus supplement related to the proposed public offering and our most recent Annual Report on Form 20-F filed with the SEC on
March 2, 2022 particularly in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". In
light of the significant uncertainties in our forward-looking statements, you should not place undue reliance on these statements or regard these statements as a
representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all.
Any forward-looking statement made by us in this presentation speaks only as of the date of this presentation and represents our estimates and assumptions
only as of the date of this presentation. Except as required by law, we assume no obligation to update these statements publicly, whether as a result of new
information, future events, changed circumstances or otherwise after the date of this presentation.
This presentation concerns product candidates that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and
Drug Administration, European Medicines Agency or other foreign regulatory authorities. These product candidates are currently limited by U.S. Federal law to
investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo,
2
TransCon, and SKYTROFA are trademarks owned by the Ascendis Pharma group.
March 2022 Ascendis Pharma A/S.
TransCon PTH is an investigational product candidate.
For investor communication only.
Not for use in product promotion. Not for further distribution.
ascendis
pharmaView entire presentation